Onconetix, Inc.
ONCO
Rank in Stocks
#32697
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed... Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Share Price
$3.58
Last synced: 2026-11-09
Market Cap
$1.28M
Change (1 day)
-48.49%
Change (1 year)
-97.38%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Onconetix, Inc. (ONCO)
Category
Healthcare
EPS for Onconetix, Inc. (ONCO)
EPS as of June 2026 TTM: $-87.36
According to Onconetix, Inc.'s latest financial reports, its current EPS (TTM) is $-87.36. At the end of 2025 the company had an EPS of $-47.30, an increase over its 2024 EPS of $-520.93.
EPS history for Onconetix, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-87.36 | 84.69% |
| 2025 | $-47.30 | -90.92% |
| 2024 | $-520.93 | 1,981.33% |
| 2023 | $-25.03 | 7,937.44% |
| 2022 | $-0.31 | 251.47% |
| 2021 | $-0.09 | 121.50% |
| 2020 | $-0.04 | 87.79% |
| 2019 | $-0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -117.93% |
US
|
|
| $-7.07 | -91.91% |
US
|
|
| $-5.29 | -93.94% |
AU
|
|
| $12.88 | -114.74% |
BE
|
|
| $21.56 | -124.68% |
NL
|
Questions about Onconetix, Inc.'s earnings per share (EPS)
What is Onconetix, Inc.'s earnings per share (EPS)?
Onconetix, Inc.'s earnings per share (EPS) over the last twelve months is $-87.36, as of Jun 2026.
What was Onconetix, Inc.'s earnings per share (EPS) in 2025?
In 2025, Onconetix, Inc.'s earnings per share (EPS) was $-47.30, compared with $-520.93 in 2024.
How has Onconetix, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Onconetix, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.04) and lowest in 2024 ($-520.93).
How does Onconetix, Inc.'s earnings per share (EPS) compare with similar companies?
Onconetix, Inc.'s earnings per share (EPS) ($-87.36) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.